All In Biotech

Investigational drug · Phase 2

JYP0061

Also called: Experimental Drug Group

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders.

Phase 2

Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "JYP0061"

First trial start

2023

May 24, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JYP0061", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Moderate-to-severe Atopic Dermatitis
  • Neuromyelitis Optica Spectrum Disorders

Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "JYP0061" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Moderate-to-severe Atopic Dermatitis

  • SHR-1819Phase 38 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis

  • SHR-1905Phase 36 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis

  • RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials

    Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata

  • AK139Phase 26 trials

    Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria

  • QLS12010Phase 23 trials

    Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.